A Phase 3 interventional study of immunization procedures in Rabies Human and Antibody, sponsored by Changchun Zhuoyi Biological Co., Ltd. Completed at 1 site in China. Open to participants aged 10 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Changchun Zhuoyi Biological Co., Ltd · Phase 3, Interventional, and Prevention
To evaluate the non inferiority of the immunogenicity of the test vaccine inoculated according to the four dose immunization program over the five dose immunization program and the batches consistency of immunogenicity according to five dose immunization procedures.
114 studies on the registry are indexed under Rabies; 15 are open to participants now.
This study's enrollment of 2,100 is above the median of 201 across 104 interventional studies indexed under Rabies.
Browse Rabies studies →Changchun Zhuoyi Biological Co., Ltd is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Inoculate rabies vaccine according to 1-1-1-1 immunization procedure
Biological: immunization procedures
Inoculate rabies vaccine according to 1-1-1-1-1 immunization procedure
Biological: immunization procedures
The subjects were vaccinated with rabies vaccine according to different immunization procedures
Positive conversion rate of 14 days
\- 14 days after the first dose of inoculation, the positive conversion rate of serum neutralizing antibody.
Time frame: 6 months
Antibody Geometric Mean Titer (GMT) of 14 days
\- 14 days after the first dose of inoculation, the Geometric Mean Titer (GMT) of serum neutralizing antibody .
Time frame: 6 months
Positive conversion rate of 42 days
\- The seroconversion rate of serum neutralizing antibody that 42 days after the first dose of inoculation.
Time frame: 6 months
Advertise Events (AE) incidence within 1 month
\- The distribution of AE incidence in different time periods (including all, within 30 minutes, 0-3 days, 0-7 days, 8-30 days) after each dose of inoculation;
Time frame: 6 months
Serious Adverse Events (SAE) incidence within 6 months
\- Incidence rate of SAE within 6 months from the first dose of inoculation to the full course of inoculation.
Time frame: 12 months
Antibody test of 28 days
Detection of serum neutralizing antibody 28 days after the first dose of inoculation
Time frame: 6 months
Antibody GMT of 42 days
The serum neutralized antibody GMT 42 days after the first dose of inoculation;
Time frame: 6 months
Antibody test within 12 months
The serum neutralizing antibody was detected in 3 timepoints within 12 months after the whole vaccination.
Time frame: 18months
Plan to share: Yes — safety and antibody results.
Supporting information: Study protocol, Informed consent form
Time frame: before December 2024.
Access criteria: public to all.
No publications or documents are linked to this record.
Ran from Jun 2022 to primary completion in Nov 2022, 5 months.
Of 19 phase 3 interventional studies under Rabies, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 21. This study's 5 months is below that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Nov 2024 → Nov 2022 and completion Dec 2024 → Aug 2023.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Changchun Zhuoyi Biological Co., Ltd